Published in Cerebrovasc Dis on August 22, 2005
Fatigue in the acute phase after first stroke predicts poorer physical health 18 months later. Neurology (2013) 2.17
Serum cytokine and glucose levels as predictors of poststroke fatigue in acute ischemic stroke patients. J Neurol (2011) 1.03
Fatigue after stroke: baseline predictors and influence on survival. Analysis of data from UK patients recruited in the International Stroke Trial. PLoS One (2011) 1.01
Frequency, characterisation and therapies of fatigue after stroke. Neurol Sci (2008) 0.95
Ischaemic stroke in young adults: risk factors and long-term consequences. Nat Rev Neurol (2014) 0.93
Acute basal ganglia infarcts in poststroke fatigue: an MRI study. J Neurol (2009) 0.93
Poststroke fatigue: who is at risk for an increase in fatigue? Stroke Res Treat (2011) 0.91
The effects of fatigue, pain, and depression on quality of life in ischemic stroke patients: the Bergen Stroke Study. Vasc Health Risk Manag (2012) 0.89
The Course of Fatigue during the First 18 Months after First-Ever Stroke: A Longitudinal Study. Stroke Res Treat (2011) 0.89
CT and Clinical Predictors of Fatigue at One Month after Stroke. Cerebrovasc Dis Extra (2013) 0.82
Can the Fatigue Severity Scale 7-item version be used across different patient populations as a generic fatigue measure--a comparative study using a Rasch model approach. Health Qual Life Outcomes (2014) 0.82
Determinants of fatigue after first-ever ischemic stroke during acute phase. PLoS One (2014) 0.81
The diagnostic value of endothelial function as a potential sensor of fatigue in health. Vasc Health Risk Manag (2010) 0.81
Post-stroke pain on long-term follow-up: the Bergen stroke study. J Neurol (2010) 0.81
Poststroke fatigue and depression are related to mortality in young adults: a cohort study. BMJ Open (2013) 0.80
Factors Associated with Poststroke Fatigue: A Systematic Review. Stroke Res Treat (2015) 0.77
Prevalence of fatigue in patients 3 months after stroke and association with early motor activity: a prospective study comparing stroke patients with a matched general population cohort. BMC Neurol (2015) 0.76
Younger stroke survivors' experiences of family life in a long-term perspective: a narrative hermeneutic phenomenological study. Nurs Res Pract (2012) 0.76
Mental fatigue and cognitive impairment after an almost neurological recovered stroke. ISRN Psychiatry (2012) 0.76
Inflammation and the Silent Sequelae of Stroke. Neurotherapeutics (2016) 0.75
Post-stroke Mood and Emotional Disturbances: Pharmacological Therapy Based on Mechanisms. J Stroke (2016) 0.75
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet (2013) 4.62
[Diffusion-weighted MR in transient ischemic attacks]. Tidsskr Nor Laegeforen (2015) 3.21
Subpial demyelination in the cerebral cortex of multiple sclerosis patients. J Neuropathol Exp Neurol (2003) 2.85
A high-density screen for linkage in multiple sclerosis. Am J Hum Genet (2005) 2.50
Epstein-Barr virus is a necessary causative agent in the pathogenesis of multiple sclerosis: no. Mult Scler (2013) 1.67
NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial. Lancet Neurol (2009) 1.58
Risk of MS is not associated with exposure to crude oil, but increases with low level of education. Mult Scler (2011) 1.54
Retinol levels are associated with magnetic resonance imaging outcomes in multiple sclerosis. Mult Scler (2012) 1.50
Effects of amiodarone and thoracic epidural analgesia on atrial fibrillation after coronary artery bypass grafting. J Cardiothorac Vasc Anesth (2004) 1.45
Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders. Neurology (2014) 1.45
[Patients with acute cerebral infarction admitted to stroke unit]. Tidsskr Nor Laegeforen (2011) 1.45
Retracted [Optic neuritis--diagnosis, treatment and follow up]. Tidsskr Nor Laegeforen (2005) 1.43
[a woman with recurrence of venous and arterial thrombosis]. Tidsskr Nor Laegeforen (2011) 1.39
[New diagnostic criteria in multiple sclerosis]. Tidsskr Nor Laegeforen (2003) 1.38
Cerebral arterial vasospasm. Tidsskr Nor Laegeforen (2011) 1.38
Vitamin D and disease activity in multiple sclerosis before and during interferon-β treatment. Neurology (2012) 1.27
Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort. Mult Scler (2013) 1.22
Demographic and geographic vascular risk factor differences in European young adults with ischemic stroke: the 15 cities young stroke study. Stroke (2012) 1.20
Health-related quality of life among young adults with ischemic stroke on long-term follow-up. Stroke (2006) 1.18
Nonsteroidal anti-inflammatory drug use and breast cancer risk: a Danish cohort study. Eur J Cancer Prev (2008) 1.18
Caregiver burden in multiple sclerosis: the impact of neuropsychiatric symptoms. J Neurol Neurosurg Psychiatry (2007) 1.17
Admission C-reactive protein after acute ischemic stroke is associated with stroke severity and mortality: the 'Bergen stroke study'. BMC Neurol (2009) 1.17
ω-3 fatty acid treatment in multiple sclerosis (OFAMS Study): a randomized, double-blind, placebo-controlled trial. Arch Neurol (2012) 1.15
Discriminating variable test and selectivity ratio plot: quantitative tools for interpretation and variable (biomarker) selection in complex spectral or chromatographic profiles. Anal Chem (2009) 1.10
[Re: Unethical of neurologists not to offer patients with multiple sclerosis chemotherapy with autologous stem cell support]. Tidsskr Nor Laegeforen (2014) 1.08
Upper gastrointestinal bleeding among users of NSAIDs: a population-based cohort study in Denmark. Br J Clin Pharmacol (2002) 1.08
[Re: What is good treatment of acute stroke?]. Tidsskr Nor Laegeforen (2015) 1.07
Progressive multifocal leucoencephalopathy in an immunocompetent patient with favourable outcome. A case report. BMC Neurol (2010) 1.05
A rare variant of the TYK2 gene is confirmed to be associated with multiple sclerosis. Eur J Hum Genet (2009) 1.05
Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. Mult Scler (2012) 1.04
Month of birth as a latitude-dependent risk factor for multiple sclerosis in Norway. Mult Scler (2012) 1.04
European Stroke Organisation recommendations to establish a stroke unit and stroke center. Stroke (2013) 1.04
Inverse relationship of baseline body temperature and outcome between ischemic stroke patients treated and not treated with thrombolysis: the Bergen stroke study. Acta Neurol Scand (2010) 1.03
Occipital lobe infarctions are different. Vasc Health Risk Manag (2007) 1.02
Dietary vitamin D3 supplements reduce demyelination in the cuprizone model. PLoS One (2011) 1.02
The Norwegian tenecteplase stroke trial (NOR-TEST): randomised controlled trial of tenecteplase vs. alteplase in acute ischaemic stroke. BMC Neurol (2014) 1.02
Risk for cancer in a cohort of patients hospitalized for schizophrenia in Denmark, 1969-1993. Schizophr Res (2004) 1.00
How long can you keep working with benign multiple sclerosis? J Neurol Neurosurg Psychiatry (2010) 0.98
Instrumental assessment of atopic eczema: validation of transepidermal water loss, stratum corneum hydration, erythema, scaling, and edema. J Am Acad Dermatol (2006) 0.97
Poor sleep in patients with multiple sclerosis. PLoS One (2012) 0.95
Discovery and initial verification of differentially abundant proteins between multiple sclerosis patients and controls using iTRAQ and SID-SRM. J Proteomics (2012) 0.95
Upregulation of immunoglobulin-related genes in cortical sections from multiple sclerosis patients. Brain Pathol (2009) 0.93
Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab. Mult Scler (2011) 0.92
Diffusion-weighted lesions in stroke patients with transient symptoms--where are they located? Cerebrovasc Dis (2014) 0.92
Vitamin D-dependent rickets as a possible risk factor for multiple sclerosis. Arch Neurol (2008) 0.92
Oligoclonal band status in Scandinavian multiple sclerosis patients is associated with specific genetic risk alleles. PLoS One (2013) 0.92
Sex ratio of multiple sclerosis in persons born from 1930 to 1979 and its relation to latitude in Norway. J Neurol (2013) 0.92
Pre-analytical influence on the low molecular weight cerebrospinal fluid proteome. Proteomics Clin Appl (2007) 0.92
Serum albumin in ischemic stroke patients: the higher the better. The Bergen Stroke Study. Cerebrovasc Dis (2009) 0.91
Onconeural antibodies: improved detection and clinical correlations. J Neuroimmunol (2010) 0.91
A multivariate approach to reveal biomarker signatures for disease classification: application to mass spectral profiles of cerebrospinal fluid from patients with multiple sclerosis. J Proteome Res (2010) 0.91
mtDNA nt13708A variant increases the risk of multiple sclerosis. PLoS One (2008) 0.90
Lipoatrophy: a non-reversible complication of subcutaneous interferon-beta 1a treatment of multiple sclerosis. J Neurol (2006) 0.90
Underfunding of stroke research: a Europe-wide problem. Stroke (2004) 0.90
Prevalence and incidence of multiple sclerosis in Oppland County: a cross-sectional population-based study in a landlocked county of Eastern Norway. Acta Neurol Scand (2010) 0.90
Postinfectious and chronic fatigue syndromes: clinical experience from a tertiary-referral centre in Norway. In Vivo (2010) 0.89
Risk factors and their impact on carotid intima-media thickness in young and middle-aged ischemic stroke patients and controls: the Norwegian Stroke in the Young Study. BMC Res Notes (2014) 0.88
Serum uri acid: neuroprotection in thrombolysis. The Bergen NORSTROKE study. BMC Neurol (2011) 0.87
Intracerebral hemorrhage in southern Norway--a hospital-based incidence study. Eur Neurol (2012) 0.87
No evidence of association between mutant alleles of the CYP27B1 gene and multiple sclerosis. Ann Neurol (2013) 0.87
Predictors for recanalization after intravenous thrombolysis in acute ischemic stroke. J Stroke Cerebrovasc Dis (2007) 0.86
Fcgamma receptor IIIA polymorphism as a risk-factor for coronary artery disease. Atherosclerosis (2005) 0.86
The Norwegian Stroke in the Young Study (NOR-SYS): rationale and design. BMC Neurol (2013) 0.86
Biomarkers Related to Carotid Intima-Media Thickness and Plaques in Long-Term Survivors of Ischemic Stroke. Transl Stroke Res (2015) 0.85
Severity of Guillain-Barré syndrome is associated with Fc gamma Receptor III polymorphisms. J Neuroimmunol (2005) 0.85
Low body temperature associated with severe ischemic stroke within 6 hours of onset: The Bergen NORSTROKE Study. Vasc Health Risk Manag (2012) 0.85
Balance and gait improved in patients with MS after physiotherapy based on the Bobath concept. Physiother Res Int (2006) 0.85
Effects of dietary intervention on MRI activity, de- and remyelination in the cuprizone model for demyelination. Exp Neurol (2008) 0.85
Antibodies against interferon-beta in multiple sclerosis. J Neuroimmunol (2009) 0.84
The effect of physiologic derangement in patients with stroke treated with thrombolysis. J Stroke Cerebrovasc Dis (2008) 0.84
Elevated admission blood pressure and stroke severity in acute ischemic stroke: the Bergen NORSTROKE Study. Cerebrovasc Dis (2013) 0.84
Ethnic variation of Fc gamma receptor polymorphism in Sami and Norwegian populations. Immunology (2005) 0.84
TNF-alpha and -beta gene polymorphisms in multiple sclerosis: a highly significant role for determinants in the first intron of the TNF-beta gene. Autoimmunity (2002) 0.84
Comparison between Ischemic Stroke Patients <50 Years and ≥50 Years Admitted to a Single Centre: The Bergen Stroke Study. Stroke Res Treat (2011) 0.84
Chronic fatigue syndrome after Giardia enteritis: clinical characteristics, disability and long-term sickness absence. BMC Gastroenterol (2012) 0.83
Pregnancy, delivery and birth outcome in different stages of maternal multiple sclerosis. J Neurol (2008) 0.83
Interleukin-10 promoter polymorphisms in myasthenia gravis. J Neuroimmunol (2009) 0.82
Pretreatment of mass spectral profiles: application to proteomic data. Anal Chem (2007) 0.82
Arterial events after ischemic stroke at a young age: a cross-sectional long-term follow-up of patients and controls in western Norway. Cerebrovasc Dis (2007) 0.82
Lack of association with the CD28/CTLA4/ICOS gene region among Norwegian multiple sclerosis patients. J Neuroimmunol (2005) 0.82
Alterations in KLRB1 gene expression and a Scandinavian multiple sclerosis association study of the KLRB1 SNP rs4763655. Eur J Hum Genet (2011) 0.81
High incidence of infarction in the left cerebral hemisphere among young adults. J Stroke Cerebrovasc Dis (2007) 0.81
Alpha-tocopherol and MRI outcomes in multiple sclerosis--association and prediction. PLoS One (2013) 0.81
[Prostate cancer in Denmark 1943-2002]. Ugeskr Laeger (2007) 0.81
Interleukin-10 promoter polymorphisms in patients with multiple sclerosis. J Neurol Sci (2002) 0.81
Persistent middle cerebral artery occlusion associated with lower body temperature on admission. Vasc Health Risk Manag (2013) 0.81
Preadmission use of warfarin improves short-term outcome in patients with acute cerebral infarction. The Bergen Stroke Study. Cerebrovasc Dis (2009) 0.80
Effect of high-dose 1.25 dihydroxyvitamin D3 on remyelination in the cuprizone model. APMIS (2014) 0.80
The cuprizone model: regional heterogeneity of pathology. APMIS (2012) 0.80
Association of genetic markers with CSF oligoclonal bands in multiple sclerosis patients. PLoS One (2013) 0.80